Biotech | November 13, 2021
Moderna presents data from Phase 1 study of mRNA Triplet programme
The interim data combines three mRNAs into one therapy injected directly into the tumour
The interim data combines three mRNAs into one therapy injected directly into the tumour
This approval of shelf-life extension was based on the availability of additional stability data, which was submitted to CDSCO
The trial met the primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE)
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
Prostate cancer is the second-most common cancer in men and despite an increase in the number of available treatments for men with mCRPC, five-year survival remains low
The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
In his previous assignment Perfetti was associated with Fabbrica Italiana Sintetici (F.I.S) as Chief Commercial Officer
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)